We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

81 hedge funds and large institutions have $361M invested in Iovance Biotherapeutics in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

759% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $139K

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

5% more capital invested

Capital invested by funds: $345M → $361M (+$16.1M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7% less funds holding

Funds holding: 87 → 81 (-6)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
81
Holders Change
-6
Holders Change %
-6.9%
% of All Funds
2.02%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
5
Increased
31
Reduced
25
Closed
6
Calls
$1.19M
Puts
$139K
Net Calls
+$1.05M
Net Calls Change
+$2.02M

Top Buyers

1
BlackRock
BlackRock
New York
+$44.5M
2
GTC
Ghost Tree Capital
New York
+$1.65M
3
Goldman Sachs
Goldman Sachs
New York
+$1.45M
4
Victory Capital Management
Victory Capital Management
Texas
+$1.45M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.04M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.62M
2
ACP
Acuta Capital Partners
California
-$2.89M
3
SM
Sabby Management
Florida
-$1.22M
4
First Eagle Investment Management
First Eagle Investment Management
New York
-$1.04M
5
UBS Group
UBS Group
Switzerland
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$45.2M +$44.5M +6,069,679 +158,271%
Franklin Resources
2
Franklin Resources
California
$38.9M +$49.2K +6,718 +0.1%
ACA
3
Avoro Capital Advisors
New York
$33.9M +$225K +30,700 +0.7%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$28.6M -$4.62M -631,000 -14%
PA
5
Perceptive Advisors
New York
$26.6M – – –
ACP
6
Acuta Capital Partners
California
$25.4M -$2.89M -394,900 -10%
O
7
OrbiMed
New York
$25.2M – – –
Victory Capital Management
8
Victory Capital Management
Texas
$18.9M +$1.45M +197,638 +8%
BC
9
Broadfin Capital
New York
$18.7M -$947K -129,200 -5%
Vanguard Group
10
Vanguard Group
Pennsylvania
$16.7M +$191K +26,039 +1%
FM
11
Frazier Management
Washington
$16.3M – – –
QF
12
QVT Financial
New York
$10M -$832K -113,500 -8%
GTC
13
Ghost Tree Capital
New York
$8.94M +$1.65M +225,000 +23%
State Street
14
State Street
Massachusetts
$6.89M +$449K +61,248 +7%
Northern Trust
15
Northern Trust
Illinois
$5.25M +$316K +43,066 +7%
Axa
16
Axa
France
$5.19M +$2.67K +364 +0.1%
RPAM
17
Rhenman & Partners Asset Management
Sweden
$4.84M – – –
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.73M +$1.04M +142,298 +40%
Goldman Sachs
19
Goldman Sachs
New York
$1.9M +$1.45M +198,051 +351%
OM
20
Opaleye Management
Massachusetts
$1.71M -$513K -70,000 -23%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.67M +$5.07K +692 +0.3%
Charles Schwab
22
Charles Schwab
California
$1.54M +$82.2K +11,220 +6%
Allianz Asset Management
23
Allianz Asset Management
Germany
$1.42M -$20.1K -2,748 -1%
TCIM
24
TIAA CREF Investment Management
New York
$1.07M -$45.8K -6,245 -4%
VIA
25
Vident Investment Advisory
Georgia
$935K +$153K +20,920 +20%
1
2 3 4

IOVA Hedge Fund Activity: Q1 2017 in Review

81 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2017, worth a combined $361M — up 4.7% from $345M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IOVA and 5 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.

The largest buyer was BlackRock, adding an estimated $44.5M. The largest seller was Fidelity Investments, cutting an estimated $4.62M.

  • 81 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2017, down from 87 in Q4 2016.
  • Funds reported $361M of Iovance Biotherapeutics stock for Q1 2017, up 4.7% quarter-over-quarter.
  • 5 funds opened new Iovance Biotherapeutics positions in Q1 2017 and 6 closed out, a net change of -1 holder.
  • The largest Iovance Biotherapeutics buyer in Q1 2017 was BlackRock, an estimated $44.5M added.
  • The largest Iovance Biotherapeutics seller in Q1 2017 was Fidelity Investments, an estimated $4.62M sold.

Based on aggregated 13F filings for Q1 2017.